NOV 10, 2019 3:41 PM PST

Promising Results for New Vaccine Against Dengue Fever

WRITTEN BY: Annie Lennon

Dengue fever is an illness transmitted by mosquito bites. Affecting around 390 million people per year, if left untreated, its mortality rate is 20%. Although vaccines have been developed to tackle the condition, so far, they have been limited in efficacy. This may change however thanks to promising preliminary results from a new vaccine developed by Japanese pharmaceutical firm, Takeda. 

The first vaccine for the disease, known as Dengvaxia, was approved in 2016. Although effective in some cases, it has limited utility due to its reputation for increasing the risk of serious illness among people with no previous exposure to Dengue fever, and is thus only used on those who have already been infected with the virus. 

Unlike Dengvaxia, the new vaccine developed by Takeda seems to be effective for both those who have previously had Dengue Fever and those with no previous exposure. 

Based on a weakened form of the live virus, researchers compared the new drug to a placebo in a trial of over 20,000 children aged between 4 and 16 in 26 locations around Asia and Latin America. With each child receiving two doses of the vaccine three months apart, so far results from a one-year follow up after the second dose show the vaccine to be 80.2% effective (Steenhuysen: 2019). 

Out of the four versions of the Dengue virus in circulation, the new vaccine appears to offer good protection against one type, and partial protection against two others. Although exciting news for regions where this condition is widespread and researchers alike however, a three-year follow-up is still necessary to confirm its protective results are stable (Wong: 2019). 

According to Duane Gubler at Duke-NUS Medical, Singapore, a patent holder of the new vaccine, “If these results hold during long-term follow-up and if the vaccine shows a significant reduction in severe disease, this vaccine, if used properly, could have a major impact on our ability to prevent and control the pandemic of dengue currently ravaging the world (ibid).”,

Rajeev Venkayya, president of Takeda added, “While more data is needed to fully understand the safety and efficacy profile of TAK-003, these findings strongly suggest that it could help address the massive global burden of dengue in all populations. We look forward to sharing more data in the coming weeks, and engaging health authorities and the scientific, public health and medical communities on these findings, priorities for future evidence generation, and ways we can work together to maximise the reach and impact of this vaccine upon licensure (BL: 2019).”

 

Sources 

 

Steenhuysen, Julie: Reuters

Wong, Sam: New Scientist

BL: The Hindu Business Line

 

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
SEP 20, 2021
Microbiology
Antibiotics and Viruses Team Up to Kill Drug-Resistant Bugs
SEP 20, 2021
Antibiotics and Viruses Team Up to Kill Drug-Resistant Bugs
Before antibiotics became a common treatment for infections, researchers considered using viruses that infect bacteria, ...
NOV 04, 2021
Immunology
Trial Flop: Experimental Asthma Treatment Makes Symptoms Worse
NOV 04, 2021
Trial Flop: Experimental Asthma Treatment Makes Symptoms Worse
One causes red, scaly patches on the skin, and the other triggers breathing difficulties, but there are some common thre ...
NOV 04, 2021
Cancer
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
NOV 04, 2021
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
Despite the incremental success immune checkpoint inhibitors (ICI) have attributed to the cancer treatment landscape rec ...
NOV 18, 2021
Cannabis Sciences
Could Cannabis-Based Compounds Be the Next New Class of Antibiotics?
NOV 18, 2021
Could Cannabis-Based Compounds Be the Next New Class of Antibiotics?
According to the Centers for Disease Prevention and Control (CDC), antibiotic-resistant bacterial or fungal strains infe ...
NOV 23, 2021
Health & Medicine
No Short Term Effects of THC-positive Breast Milk
NOV 23, 2021
No Short Term Effects of THC-positive Breast Milk
A recent study found that THC does not have short-term negative effects on an early, premature baby’s health. Rese ...
NOV 20, 2021
Neuroscience
Fear balance - the brain and body communicate to maintain fear within an adaptive range
NOV 20, 2021
Fear balance - the brain and body communicate to maintain fear within an adaptive range
We have all experienced the emotion of fear. Although what one individual might fear (e.g. rollercoasters or snakes), mi ...
Loading Comments...